Editas Medicine, Inc. Common Stock (EDIT) Stock Price
EDITStock
$3.16+19.25%52W
Market Cap$485.31M
P/E—
PEG Ratio—
Div yield—
Beta2.02
EDIT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)37.83%
Price vs S&P 500 (4W)17.70%
VGM Score54.79
EDIT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.28 | -$0.15 | +46.23%(+$0.13) | |
| Q1 2026 | -$0.24 | -$0.26 | -7.61%(-$0.02) | |
| Q4 2025 | -$0.21 | -$0.06 | +72.08%(+$0.15) | |
| Q3 2025 | -$0.38 | -$0.28 | +27.17%(+$0.10) | |
| Q2 2025 | -$0.38 | -$0.32 | +15.32%(+$0.06) |
EDIT Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
3.75
3.79
3.79
3.78
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EDITEditas Medicine, Inc. Common Stock | C | C | B | $3.16 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Editas Medicine, Inc. Common Stock
Editas Medicine is a clinical-stage genome editing company developing CRISPR/Cas9-based therapeutics to treat serious genetic diseases. The company's proprietary platform uses a Cas9 enzyme-guide RNA complex to precisely repair disease-causing DNA mutations. Editas is advancing a pipeline of genome editing programs toward clinical and commercial applications.